Researcher
Rik
- Keywords:Medicine
- Disciplines:Natural sciences
Affiliations
- Hematology (Department)
Member
From1 Jul 2012 → Today - Hematology (Research group)
Member
From1 Oct 2003 → Today - Clinical sciences (Department)
Member
From8 Apr 2019 → Today - Clinical sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Laboratory of Molecullar and Cellular Therapy (Research group)
Member
From28 Feb 2013 → 1 Oct 2019 - Immunology and Microbiology (Department)
Member
From1 Dec 2006 → 31 Dec 2013 - Immunology and Microbiology (Department)
Member
From1 Dec 2003 → 30 Sep 2006
Publications
31 - 40 of 56
- Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.(2008)
Authors: Sonja Verheyden, S. Ferrone, A. Mulder, F. Claas, Rik Schots, B. De Moerloose, Y. Benoit, Christian Demanet
Pages: 855-865 - Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Authors: Nc Munshi, Kc Anderson, P. Leif Bergsagel, John D. Shaughnessy, Jr, A. Palumbo, Brian Durie, Rafael Fonseca, Ak Stewart, J.l. Harousseau, Meletios Dimopoulos, et al.
Pages: 4696-4700 - VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
Authors: Ma Dimopoulos, Pg Richardson, R Schlag, Nk Khuageva, O Shpilberg, Efstathios Kastritis, M. Kropff, Mt Petrucci, M. Delforge, Julia Alexeeva, et al.
Pages: 6086-6093 - Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
Authors: L Tucunduva, A Ruggeri, G Sanz, S. Furst, J. Cornelissen, Rik Schots
Pages: 749-57 - Recent advances in myeloma treatment
Authors: Rik Schots
Pages: 223-229 - Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Authors: L Benboubker, Ma Dimopoulos, A Dispenzieri, J Catalano, Ar Belch, M. Cavo, A. Pinto, Katja Weisel, Heinz Ludwig, N. Et Al. Bahlis, et al.
Pages: 906-917 - The outcome of patients with Philadelphia chromosome negative/bc-abl negative chronic myelogenous leukaemia after allogeneic stem cell transplantation: a restrospective study of the CML subcommittee of the Chronic Leukemia Working Party (EBMT)
Authors: H. Thomssen, A. Van Biezen, R. Brand, N. Russell, Jane F. Apperley, R. Foa, Rik Schots, V; Koza, M. Bornhauser, E. Olavarria, et al.
Pages: 34-34 - Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Authors: Jf San Miguel, R Schlag, Nk Khuageva, Ma Dimopoulos, O Shpilberg, M. Kropff, I. Spicka, Mt Petrucci, A. Palumbo, Os Samoilova, et al.
Pages: 906-917 - Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone
Authors: J.l. Harousseau, A. Palumbo, Pg Richardson, R Schlag, Ma Dimopoulos, O Shpilberg, M. Kropff, M. Delforge, Rik Schots, M. Cavo
Pages: 959-959 - A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
Authors: Jp Cazenave, G. Folléa, L. Bardiaux, Jm Boiron, B. Lafeuillade, M. Debost, B. Lioure, J.l. Harousseau, E. Deconinck, R. Tabrizi, et al.
Pages: 2362-2375